The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
The pro‐inflammatory cytokine interleukin‐1 (IL‐1) drives the pathogenesis of several inflammatory diseases. Recent studies have revealed that 2‐indolinones can modulate cytokine responses. Therefore, we screened several 2‐indolinone derivatives in preliminary studies to develop agents with anti‐IL‐1 activity. First, the putative efficacies and binding interactions of 2‐indolinones were evaluated...
Background
B7 homolog 3 (B7‐H3) is an immunomodulatory molecule that is highly expressed in prostate cancer (PCa) and belongs to the B7 superfamily, which includes PD‐L1. Immunotherapies (antibodies, antibody‐drug conjugates, and chimeric antigen receptor T cells) targeting B7‐H3 are currently in clinical trials; therefore, elucidating the molecular and immune microenvironment correlates of B7‐H3...
Background
The detection rate of clinically significant prostate cancer has improved with the use of multiparametric magnetic resonance imaging (mpMRI). Yet, even with MRI‐guided biopsy 15%–35% of high‐risk lesions (Prostate Imaging‐Reporting and Data System [PI‐RADS] 4 and 5) are histologically benign. It is unclear if these false positives are due to diagnostic/sampling errors or pathophysiological...